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Abstract
Approximately 75% of bladder cancers are non-muscle invasive (NMIBC). Of these, up to 53% of cases progress
to life-threatening muscle-invasive bladder cancer (MIBC). Patients with high-grade stage T1 (HGT1) NMIBC fre-
quently undergo radical cystectomy (RC), although this represents overtreatment for many. Identification of pro-
gressors versus non-progressors could spare unnecessary treatment. Recent studies have confirmed that
urothelial carcinoma is composed of two main molecular subtypes, basal and luminal, with 12% of basal tumours
exhibiting epithelial-to-mesenchymal transition (EMT). Levels of immune cell infiltration have been shown to be
subtype-specific. Here, we performed immunohistochemistry (IHC) for 11 antibodies relating to molecular sub-
types or EMT in 26 cases of HGT1 urothelial carcinoma cases with 6 matched samples subsequently obtained at
cystectomy (n = 6; 1 muscle-invasive, 5 non-muscle-invasive; 3 = pTis, 1 = pT1, 1 = pTa) and at recurrence
(n = 2, pT2). RNAScope was also conducted in a subset. Expression patterns in HGT1 specimens versus MIBC (pT2
+) were examined, and correlated with disease-specific survival (DSS). Levels of stromal tumour-infiltrating lym-
phocytes (sTILs) were assessed manually to determine whether lymphocyte infiltration was associated with DSS
and whether differences existed between HGT1 and MIBC. Molecular subtype markers demonstrated increased
prognostic potential compared to the EMT markers assessed. Increased expression of the luminal markers FOXA1
and SCUBE2, were found to be significantly associated with better DFS. No EMT markers were significantly asso-
ciated with DFS. In areas of non-invasive papillary urothelial carcinoma, but not invasive carcinoma, sTIL levels
were found to be significantly associated with DFS. While differences were observed between HGT1 cases that
progressed versus those that did not, a larger cohort study is required for validation of these findings. Taken
together, an emphasis on molecular subtype markers, rather than EMT markers, may be preferable when studying
biomarkers of HGT1 urothelial carcinoma in the future.
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Introduction
Approximately 75% of newly diagnosed bladder cancers
are non-muscle invasive (NMIBC), rather than muscle-
invasive (MIBC) [1], with 25% of cases showing lamina
propria invasion. Up to 53% of these cases can progress
from NMIBC (pTa or pT1) to life-threatening muscle-
invasive bladder cancer (MIBC, pT2+) [2]. Patients with
high-grade stage T1 (HGT1) NMIBC may undergo radi-
cal cystectomy (RC), although this represents over-
treatment in many patients [2]. There is therefore an
urgent clinical need to identify likely progressors versus
non-progressors, for patients to be given appropriate treat-
ment promptly or to be spared unnecessary treatment.
Cancer cells undergoing epithelial-to-mesenchymal tran-
sition (EMT), a mechanism of invasion, are characterised
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by a loss of proteins that mediate cell–cell contacts
(e.g. E-cadherin) and increased expression of markers that
promote a motile cell state (vimentin and N-cadherin)
[3]. In some cases, EMT is a reversible process, with
mesenchymal-to-epithelial transition (MET) also possible.
This is observed in normal embryonic development but has
also been demonstrated in cancer cells in vitro and in
mouse xenografts [3,4]. The reversible nature of EMT
makes it an attractive therapeutic target. Indeed, factors
relating to EMT have been shown to be druggable targets
[5,6]. Notably, monoclonal antibody (mAb) and small mol-
ecule targeting of receptor tyrosine kinases (RTKs), activa-
tion of which can promote EMT, have either been
approved or are under clinical trial [6]. If EMT could be
prevented, halted or reversed in patients identified as being
at risk of progression to MIBC, this could obviate the need
for cystectomy. While EMT has been associated with blad-
der cancer progression and metastasis at the genomic level
[7], the patterns of EMT markers at the protein level and
the contribution to HGT1 disease are not well understood.
A range of studies have investigated molecular subclas-
sification of bladder and recently a six-class consensus
classification has been reached [8–12]. Although each
classification varies slightly, with Sjodahl et al [8] also
evaluating NMIBC, two major subtypes, basal and lumi-
nal, have emerged with further subclassifications within
them. Approximately 12% of tumours are claudin-low
(a basal subtype) and exhibit EMT; in contrast, luminal
tumours (66% of cases) maintain E-cadherin expression,
demonstrating a link between molecular subtype and
EMT [10]. Ultimately, despite the large number of inde-
pendent studies investigating the molecular subtypes of
bladder cancer, it is the two main subtypes, basal and
luminal, that are common to all studies [13]. However,
these are not currently used in clinical practice.
In the latest TCGAmolecular subtype study, one of the
luminal subtypes, luminal papillary (LumP), was found
to have a low risk for metastasis [14]. This implies that
for HGT1 disease, the molecular subtype of the tumour
may contribute to risk of progression to MIBC. Different
oncogenic mechanisms are also present between the dif-
ferent consensus molecular subtypes. For instance, LumP
tumours are strongly characterised by increased FGFR3
transcriptional activity as opposed to basal/squamous
(Ba/Sq) tumours, which employ EGFR mechanisms [12].
Bladder cancer is highly influenced by the immune
system. This is particularly reflected in the fact that
administration of Bacillus–Calmette–Guerin (BCG) has
been used since the 1970s as a proven effective treatment
of high-grade NMIBC to prevent progression to MIBC
[15]. This stimulation of the immune system therefore
has the potential, in some cases, to act as a ‘brake’ to pro-
gression. The importance of immune characteristics,
particularly with respect to immune infiltration, is
reflected in the latest MIBC molecular subtypes consen-
sus [12]. Differences in the overall level and components
of infiltration was dependent on subtype. For example,
the LumP, luminal unstable and neuroendocrine-like sub-
types all exhibited low levels of immune infiltration
(‘immune-cold’) compared to the luminal non-specified,
stroma-rich and Ba/Sq. These differences between sub-
types also have implications for therapy, with some
Ba/Sq tumours likely to respond well to immunother-
apies, while other tumours, such as LumP, are likely to
benefit from other forms of treatment.
Tumour infiltrating lymphocytes (TILs) are important in
a range of different cancers and, generally, increased TILs
are associated with better prognosis [16–19]. Numerous
groups have investigated intratumoural, intra-epithelial
and stromal TILs (sTILs) [20]. sTILs are located
between carcinoma cells either in a clustered or dis-
persed fashion and have no direct contact or interaction
with the tumour cells in contrast to TILs. Recent studies
have shown sTIL evaluation by pathologists can predict
response to treatment with greater consistency than TIL
evaluation [20].
The aims of this study were, first, to determine
whether an integrated panel of 11 antibodies relating to
bladder cancer molecular subtypes or EMT exhibited
differential expression patterns in HGT1 specimens ver-
sus muscle-invasive disease, and whether differences
were associated with disease-specific survival (DSS).
Second, we wanted to determine whether differences in
molecular subtype-specific mRNA expression correlated
with survival and/or progression to muscle-invasive dis-
ease, using chromogenic RNAScope in situ hybridisation,
and whether lymphocyte infiltration played a crucial role
in this. This study was a pilot study involving a small
number of cases but a relatively large panel of antibodies,
with a view to identifying a smaller panel of antibodies to
study in a larger cohort.
We hypothesised that HGT1 tumours with a propensity
for EMT, high basal marker expression (at protein and
mRNA level) and high sTIL expression would be more




Patients with HGT1 urothelial carcinoma of the blad-
der diagnosed between 2009 and 2015 were identified
in the Oxford Radcliffe Biobank (ORB; n = 26).
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Under ethical approval (South Central Oxford REC C
09/H0606/5+5), 4 μm-thick sections were taken from
formalin-fixed paraffin-embedded (FFPE) tissue
obtained at transurethral resection (TURBT) from these
patients. While for most patients this was their first presen-
tation with bladder cancer, two were noted to have had
previous HGT1 disease on their pathology reports (one
7 years previously who subsequently had a cystopro-
statectomy) and one to have had previous low grade
NMIBC. Sections were also taken from samples in patients
whose tumour recurred (T2 samples at recurrence [n = 2]
or obtained at cystectomy [n = 6; 1 muscle-invasive,
5 NMIBC; 3 = pTis, 1 = pT1, 1 = pTa]). Corresponding
H&E stained sections were assessed by a consultant histo-
pathologist (LB) and normal urothelium, carcinoma in
situ (CIS), papillary tumour and invasive tumour regions
(T1 or T2), avoiding diathermied areas and crush artefact,
were outlined to aid subsequent analysis.
RNAScope
A subset of samples was used for this assay, including
HGT1 (n = 13) and recurrence/cystectomy cases (n = 4).
Immunohistochemistry
Automated immunohistochemistry (IHC) was conducted
on the sections using a Bond-max autostainer (Leica Mic-
rosystems, GmbH, Wetzlar, Germany). Sections were
incubated with primary antibodies at the dilutions and
incubation times described in Supplementary material,
Table S1. Stained slides were digitised using an Aperio
ScanScope CS2 digital slide scanner (Leica Micro-
systems) at ×400 total magnification. Positive and nega-
tive controls were included in all runs (see Supplementary
material, Figure S1). See supplementary material, Mate-
rials and methods for additional information.
RNAScope in situ hybridisation
RNAScope in situ hybridisation (ISH) was performed on
FFPE tissue sections (6 μm) as per the manufacturer’s
guidelines (Advanced Cell Diagnostics, Hayward, CA,
USA). Hybridisation probes used were FGFR3, EGFR,
SCUBE2 and ZEB2. See Supplementary material,
Table S2 for further details. Probes were added to each tis-
sue section and allowed to incubate for 2 h at 40C. For
detection, the RNAScope 2.5 Detection Reagent—Red kit
was used (Cat#322360; Advanced Cell Diagnostics, Hay-
ward, CA, USA). Positive control sections detected the
presence of human peptidylprolyl isomerase B (hs-PPIB)
and DapB in negative control sections; these were included
in each assay (representative images in Supplementary
material, Figure S2). See supplementary material, Mate-
rials and methods for additional information.
IHC and ISH assessment
Antibodies
Antibodies used are shown in Supplementary material,
Table S1. To assess EMT, N/E-cadherin, Axl,
vimentin and slug/snail antibodies were used. For the
molecular subtypes, basal markers included CK5/6,
CK14 and CD44; luminal markers were GATA3,
FOXA1 and CK20. See supplementary material, Mate-
rials and methods for further details.
Immunohistochemistry assessment
For Cytokeratins 5/6, 14 and 20, CD44, vimentin and
Axl, cases were classified as negative or positive based
on criteria from the literature (by ECO; Table 1). For
FOXA1, GATA3, E-cadherin, N-cadherin and slug/snail,
staining was assessed using a semi-quantitative H-score
method in papillary (n = 24–28), invasive (n = 14–16),
normal (n = 5–8) and CIS (n = 3–5) regions (by ECO)
[21]. See supplementary material, Materials and methods,
and Figure S3 for more information.
RNAScope in situ hybridisation quantification
To quantify the RNAScope staining, HALO software with
an accompanying ISH algorithm was utilised. Slides were
digitalised using an Aperio CS2 bright field scanner (Leica
Biosystems, San Diego, CA, USA) and a total of 10 images
per region (papillary [n = 12], invasive [n = 13], CIS
[n = 2] and normal urothelium [n = 3]) per slide were
extracted for subsequent assessment. The ISH algorithm
was used to determine average probe area per μm2 for each
image for each region, as previously described [22]. Mean
probe area per μm2 was determined for all 10 images for
each region present on each slide. Data was analysed fur-
ther both in a regional and globally dependent manner. For
global assessment, ‘case score’ was calculated by generat-
ing an average probe area per μm2 for all regions assessed
for a particular case.
Manual sTIL assessment
Quantification of percentage coverage of stroma adjacent
to the papillary and invasive regions of tumour on Digital
Images of H&E-stained tissue sections was undertaken
following the technique described by Denkert et al
[20,23] using an open source Digital Software Platform
(QuPath) [24] by a single pathologist observer (RP).
Regions of focal invasive disease contained within papil-
lary cores were excluded from assessment. The sections
were scored in triplicate and the mean score for each
240 EC Ottley et al
© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society
of Great Britain and Ireland & John Wiley & Sons, Ltd.
J Pathol Clin Res 2020; 6: 238–251
region was used for analysis. The investigating patholo-
gist was blinded to the details and outcomes of each case.
In addition, as no formal recommendation for a clinically
relevant threshold has been previously published, sTIL
data was analysed as a linear parameter.
Statistical analysis
To determine whether any differences existed between nor-
mal, CIS and invasive regions, in terms of overall H score,
a one-way analysis of variance (ANOVA) was conducted
followed by a Tukey’s multiple comparison test. Associa-
tions of IHCmarkers, sTIL and RNAScope with DSS were
assessed using Kaplan–Meier curves and Cox proportional
hazards models. Individuals who did not die of bladder can-
cer were censored at last time known to be alive or at time
of death from other causes. Time since TURBT was used
as the time scale. Markers were used as numeric and also
dichotomised. The proportional hazards assumption was
assessed by examining scaled Schoenfeld residuals. Corre-
lation coefficients between markers were calculated. Analy-
sis was done using the Statistical Software R [25].
Results
Differential staining of basal, luminal and EMT
markers in tumour regions
We assessed whether there were differences between
normal, CIS, papillary and invasive regions of tumour
(Figure 1). Using H-score, the luminal markers
FOXA1 and GATA3 showed a similar trend. A signif-
icant difference in expression was observed between
normal and invasive areas and papillary and invasive
for both GATA3 and FOXA1. In addition, a signifi-
cant decrease in FOXA1 expression was observed
between CIS and invasive regions. For EMT markers,
E-cadherin expression was lower in invasive areas
compared to papillary, CIS and normal regions. N-
cadherin and slug/snail expression was significantly
higher in invasive areas, compared to both normal and
papillary regions.
Additional basal, luminal and EMT markers were
assessed using a positive/negative scoring system. For
all basal markers assessed (Table 1), no positive staining
was observed in normal and CIS areas and the highest
percentage of positive areas was in invasive regions;
CD44 positivity was found only in invasive regions
(31%). The luminal marker CK20 exhibited the highest
positivity (92%) in papillary regions (Table 2).
Elevated FOXA1 expression was significantly
associated with DSS
Of all of the antibodies assessed via the H-score
method, papillary FOXA1, per unit increase, was sig-
nificantly associated with DSS in terms of % positive
(p = 0.02), intensity (p = 0.035) and overall H-score
(p = 0.019; Table 3). For antibodies assessed using the
positive/negative method, no antibodies were found to
be significantly associated with DSS.
Table 1. Scoring methods used for antibodies.
Antibody Positive classification Negative classification Reference
Basal
CK-5/6 Moderate to strong staining Normal staining in basal/parabasal cells. Absent
staining
Desai et al [41]
CK-14 Moderate to strong staining Normal staining in basal/parabasal cells. Absent
staining
Desai et al [41]
CD44 Positive staining throughout the tumour cells Normal staining in basal/parabasal cells,
‘patchy-loss of staining’ or absent staining
Desai et al [41]
Luminal
CK-20 ≤10% focal positive staining or ≥10% diffuse
positive staining
Normal positive staining of superficial umbrella cells
or absent staining
Desai et al [41]
GATA3 H-score method – nuclear Walker et al [21]
FOXA1 H-score method – nuclear Walker et al [21]
EMT
Vimentin ≥5% tumour cytoplasmic positive staining ≤5% tumour cytoplasmic positive staining Sanfrancesco et al [42]
E-cadherin H-score method – membranous Walker et al [21]
N-cadherin H-score method – membranous Walker et al [21]
Slug/snail H-score method – nuclear Walker et al [21]
Axl ≥5% positive membranous and cytoplasmic staining ≤5% positive membranous and cytoplasmic staining Shieh et al [43]
Positive and negative criteria were established for relevant stains using information from the literature. H-score was determined as the product of percentage of
positive cells and staining intensity (graded 0, 1+, 2+, 3+), as previously described [21].
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Figure 1. Expression of basal, luminal and EMT markers between tumour regions for antibodies assessed via the H-score method. The
mean case H-score for normal, CIS, papillary and invasive regions are presented for all cases (HGT1, n = 26 and recurrence/cystectomy,
n = 8). Luminal antibodies (A) GATA3 and (B) FOXA1; and EMT antibodies (C) E-cadherin, (D) N-cadherin and (E) slug/snail were assessed.
Data are presented as mean case H-score  SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 with a one-way ANOVA followed by Tukey’s
multiple comparison test (not significant where p > 0.05).
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Table 2. The association of regional staining positivity with DSS.
Antibody Normal P value CIS P value Papillary P value Invasive P value
Molecular subtype markers – assessed with binary () method
CK-5/6 0 – 0 – 2 (8%) – 6 (23%) 0.833
CK-14 0 – 0 – 5 (19%) 0.493 8 (31%) 0.962
CD44 0 – 0 – 0 – 8 (31%) 0.587
CK-20 1 (4%) – 3 (12%) 0.809 24 (92%) – 9 (35%) 0.749
EMT markers – assessed with binary () method
Vim 0 – 0 – 0 – 5 (19%) 0.917
Axl 0 – 0 – 3 (12%) – 3 (12%) 0.364
P values for association with DSS are shown. For instances where P values are not present, there were either no positive regions for this antibody, or convergence
issues were present due to low numbers.
Table 3. Association with DSS for EMT and molecular subtype antibodies assessed with the H-score method.
Antibody and region logHR HR se(logHR) P value 95% CI
GATA3 papillary % positive −0.015 0.985 0.014 0.278 (0.958, 1.012)
GATA3 papillary intensity −0.564 0.569 0.379 0.136 (0.271, 1.195)
GATA3 papillary H-score −0.004 0.996 0.004 0.251 (0.988, 1.003)
GATA3 invasive % positive −0.007 0.993 0.013 0.588 (0.968, 1.019)
GATA3 invasive intensity −0.123 0.884 0.48 0.798 (0.345, 2.266)
GATA3 invasive H-score −0.002 0.998 0.005 0.741 (0.989, 1.008)
FOXA1 papillary % positive −0.05 0.952 0.021 0.020 (0.913, 0.992)
FOXA1 papillary intensity −1.228 0.293 0.581 0.035 (0.094, 0.914)
FOXA1 papillary H-score −0.012 0.988 0.005 0.019 (0.978, 0.998)
FOXA1 invasive % positive −0.044 0.957 0.024 0.066 (0.913, 1.003)
FOXA1 invasive intensity −0.877 0.416 0.584 0.133 (0.133, 1.306)
FOXA1 invasive H-score −0.015 0.985 0.01 0.139 (0.965, 1.005)
E-Cad papillary % positive 0.015 1.015 0.038 0.691 (0.943, 1.093)
E-Cad papillary H-score 0.018 1.018 0.013 0.154 (0.993, 1.044)
E-Cad invasive % positive −0.032 0.969 0.023 0.163 (0.926, 1.013)
E-Cad invasive intensity −0.377 0.686 2.157 0.861 (0.01, 47.042)
E-Cad invasive H-score 0.007 1.007 0.02 0.735 (0.967, 1.048)
N-Cad papillary % positive 0 1 0.035 0.992 (0.934, 1.07)
N-Cad papillary intensity −0.307 0.735 0.552 0.578 (0.25, 2.168)
N-Cad papillary H-score −0.002 0.998 0.005 0.703 (0.987, 1.009)
N-Cad invasive % positive −0.002 0.998 0.04 0.954 (0.923, 1.078)
N-Cad invasive intensity −0.912 0.402 1.226 0.457 (0.036, 4.439)
N-Cad invasive H-score −0.004 0.996 0.009 0.671 (0.978, 1.015)
Slug/snail papillary % positive −0.029 0.972 0.02 0.149 (0.935, 1.01)
Slug/snail papillary intensity −0.634 0.53 0.399 0.112 (0.242, 1.16)
Slug/snail papillary H-score −0.007 0.993 0.005 0.16 (0.983, 1.003)
Slug/snail invasive % positive −0.028 0.973 0.033 0.393 (0.913, 1.037)
Slug/snail invasive intensity 0.259 1.296 1.108 0.815 (0.148, 11.37)
Slug/snail invasive H-score −0.001 0.999 0.008 0.898 (0.984, 1.014)
Significant P values (p < 0.05) are in bold.
Table 4. Association of papillary and invasive sTIL% on DSS.
Tumour region logHR HR se(logHR) P value 95% CI
Papillary 0.056 1.057 0.028 0.043 (1.002, 1.116)
Invasive 0.023 1.023 0.015 0.123 (0.994, 1.054)
The significant P value (p < 0.05) is in bold.
The association with DSS was calculated for sTILs quantified from papillary and invasive regions. The logHR, HR, se(logHR), P value and 95% CI are presented.
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Differences in sTIL percentages between tumour
regions and association with DSS
Significant increases in sTIL levels were seen between pap-
illary and invasive regions (p < 0.01; Figure 2A), and see
representative images for each region (Figure 2B). Papillary
sTIL levels were significantly associated with DSS
(p < 0.05; Table 4).
RNAScope ISH probe expression patterns in
invasive and papillary regions
RNAScope ISHwas used to investigatemRNA expression
of SCUBE2, EGFR, FGFR3 and ZEB2 chromogenically
in the tissue sections. Marked differences were observed
between papillary and invasive regions for a number of
probes (Figure 3). Expression of the novel tumour suppres-
sor SCUBE2 was significantly decreased in invasive
regions compared to papillary regions (Figure 3A,
p < 0.05). Expression of FGFR3 was also significantly
decreased in invasive regions (Figure 3E, p < 0.05). No
significant differences were seen in EGFR (Figure 3C) or
ZEB2 (Figure 3G) expression. However, for ZEB2, a num-
ber of cases exhibited high expression in invasive regions
(Figure 3H).
RNAScope probe expression and correlation
with DSS
For each case, the mean case score was calculated
(Figure 4A–D). Case scores for each probe were vis-
ualised as a heat map (Figure 4E), stratified at the
median value and correlated with DSS (Figure 4F–I).
SCUBE2 was significantly associated with DSS when
stratified at the median (p = 0.022). DSS for regional
RNAScope probe expression is shown in Supplemen-
tary material, Figure S4.
Integration of staining patterns and comparison of
HGT1 cases with their respective cystectomy
samples
We consolidated all IHC, ISH and sTIL data into
expression heat maps and a correlation matrix was
generated (Figure 5A–D). For basal and luminal
staining, a range of patterns was observed. Three cases
(cases 2, 16 and 20) were positive for all basal and
luminal markers assessed. Most cases were positive
for CK20. In cases that were negative for CK20 (cases
5, 7, 10, 14, 25, 33 and 34) four demonstrated high
N-cadherin and/or slug/snail expression (cases 10, 14,
25 and 34) and four cases (cases 14, 25, 33 and 3)
demonstrated positivity for either Axl or vimentin or
both. In relation to the EMT markers assessed, inverse
expression was mostly present between E-cadherin
and N-cadherin/slug/snail. High expression of N-
cadherin was regularly associated with high nuclear
slug/snail expression. In three of five cases positive for
vimentin, positive staining for at least one basal
marker was observed (cases 17, 25 and 33) with some
cases positive for all basal markers assessed (cases
25 and 33). For all H-score IHC data, ISH case scores
and sTIL data, a correlation matrix was constructed
Figure 2. Regional sTIL expression data. (A) Differences between
papillary and invasive tumour regions. Data presented as mean
sTIL count  SEM. **p < 0.01 by unpaired Student’s t-test.
(B) Representative images for each region assessed.
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Figure 3. Regional RNAScope probe expression. Papillary and invasive region expression for RNAScope probes (A, B) SCUBE2, (C, D) EGFR,
(E, F) FGFR3 and (G, H) ZEB2 are presented. Representative papillary and invasive images are included for each probe. For ZEB2, a case
with high expression is shown in the bottom panel of (H). Data are presented as average probe area/cell (μm2)  SEM. *p < 0.05 by
unpaired Student’s t-test. Scale bars = 10 μm.
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(Figure 5B). Significant negative correlations were
observed for slug/snail and E-cadherin (p < 0.05) and
E-cadherin and ZEB2 (p < 0.05). Positive correlation
was observed for GATA3 and FOXA1 (p < 0.01).
For select HGT1 cases, where matched cystectomy
or recurrence samples were available we looked for
differences in patients who progressed beyond pT1
versus those who did not (Figure 5C). A total of three
cases with matched cystectomy/recurrence specimens
progressed to muscle-invasive disease (cases
10, 14 and 32). N-cadherin expression was higher at
baseline in cases that progressed (cases 10, 14 and 32)
versus those that did not (cases 4, 11 and 18), with
high expression maintained in two of three cases to
cystectomy/recurrence (cases 25 and 34). In baseline
HGT1 cases that progressed, only one of three cases
was positive (case 14), however, upon recurrence/
cystectomy, all cases were positive for vimentin (cases
25, 33 and 34). In contrast, all cases that did not pro-
gress were negative for Axl and vimentin at baseline
(cases 4, 11 and 18) and recurrence/cystectomy (cases
5, 15 and 20). In two of three cases that progressed,
moderate to high expression of slug/snail was evident
compared to cases that did not progress where three
cases exhibited low expression of slug/snail (cases
4, 11 and 18). For cases that did not progress, expres-
sion of both Axl and vimentin at baseline and recur-
rence/RC was negative for all cases.
GATA3 expression was relatively high in two of
three baseline cases that did not progress (cases
11 and 18) versus those that did (cases 10 and 14).
CK20 positivity was also observed in all of these
cases, while all cases were negative for CK5/6 and
CD44. For those that did progress, CK20 was negative
in all recurrence/cystectomy cases.
All cases that progressed to muscle-invasive disease
exhibited high sTIL infiltration levels and these were
associated with moderate to high expression of
N-cadherin and/or slug/snail.
For RNAScope probe expression, for baseline cases
that progressed (Figure 5D), one out of three cases
exhibited high expression of the basal probe EGFR.
Figure 4. Global RNAScope probe case score and associations with
survival. Average probe density/μm2 for each case was calculated
for each probe (A) SCUBE2, (B) FGFR3, (C) EGFR and (D) ZEB2. Data
are presented as mean probe density/μm2 per case  SEM. (E) all
RNAScope case scores for all cases presented in a heat map for-
mat. Kaplan–Meier curves for DSS stratified by median case score
for (F) SCUBE2, (G) FGFR3, (H) EGFR and (I) ZEB2.
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Figure 5. Heat maps for IHC and ISH expression and sTIL percentage. (A) IHC for molecular subtype and EMTmarkers and sTIL percentages for all cases
(HGT1 and recurrence/cystectomy). (B) A correlation matrix for all H-score, ISH and sTIL data. Significant correlations are outlined in red (p < 0.05), with
a Pearson’s product–moment correlation test. (C) Cases were then sub-divided into baseline HGT1 cases that progressed and recurrence/RC cases that
progressed. Cases were also sub-divided into heat maps for HGT1 cases that did not progress and recurrence/RC cases that did not progress.
(D) RNAScope expression data for baseline HGT1 cases that did progress and recurrence/RC cases that progressed.
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For recurrence/RC cases that progressed luminal pro-
bes SCUBE2 and FGFR3 were low for all cases, while
basal markers EGFR and ZEB2 were increased in
case 34.
Discussion
The aims of this study were to determine whether an
integrated panel of 11 antibodies relating to bladder
cancer molecular subtypes or EMT exhibited differen-
tial expression patterns in HGT1 specimens versus
muscle-invasive disease, and whether differences were
associated with DSS. The intention was to ascertain
which of the 11 antibodies would be worthy of further
validation in a larger cohort, with a view to determin-
ing their potential clinical utility. Second, we wanted
to determine whether differences in molecular
subtype-specific mRNA expression correlated with
survival and/or progression to muscle-invasive disease.
Lymphocyte infiltration levels were also investigated.
We hypothesised that high grade tumours with a com-
bined EMT and basal phenotype with low sTIL den-
sity would be more likely to progress to MIBC and
demonstrate inferior DSS.
The markers evaluated lacked association with pro-
gression to muscle-invasive disease but our study was
underpowered (n = 3). Assessment of larger cohorts is
required to determine whether EMT and molecular
subtypes play a role in progression to MIBC. The
study was constrained by available patients with
matching tissue in a single large centre.
However, interesting observations were found in
relation to DSS in a number of the markers that were
assessed. Luminal markers FOXA1 and SCUBE2 were
both significantly associated with DSS. Having been
described previously to play a role in bladder cancer,
in terms of the ability to drive a luminal subtype
[9,14,26], FOXA1 has also been shown to be involved
in other cancers, particularly breast cancer, where it
has been shown to be a prognostic factor [27,28].
In an IHC study for 16 markers which included
molecular subtype (FOXA1, GATA, CK14, FGFR3
and EGFR) and EMT (ZEB2) in 519 patients who
underwent RC, DSS was not affected by a single
marker, except in the case of FOXA1 [29]. These
authors’ findings for FOXA1 and DSS are supportive
of ours, and ZEB2 was found not to be significant.
Given the molecular subtype-specific nature and
previously described prognostic potential of lympho-
cyte infiltration in a range of tumours [12,16–19], we
assessed sTIL levels in the HGT1 cohort. Stromal
lymphocyte infiltration has been previously assessed in
HGT1 bladder cancer but failed to demonstrate prog-
nostic utility [30]. Our findings, in relation to invasive
tumour regions, support that study. However, in our
study, increased immune cell infiltration around the
base of papillary in situ regions was significantly asso-
ciated with lower DSS. When tumours have an intact
basement membrane, evasion of cytotoxic T cell
response from the stroma is less likely. A rational
hypothesis explaining why lymphocytes are aggregat-
ing around the base of non-invasive papillary areas of
tumour could be the presence of microinvasion. This
has previously been observed in both flat CIS and
non-invasive areas of papillary carcinoma [31]. The
areas of microinvasion might be difficult to discern
depending on the plane and/or orientation of the
section being examined, and microinvasion can be
overlooked if there are only a few invasive cells
[31,32]. An alternative hypothesis is that these
tumours could have acquired the capability to evade
host cytotoxic T cell responses prior to the develop-
ment of invasive disease, which could lead to localised
aggregations of lymphocytes. In this case, the histolog-
ical response pattern would subsequently persist fol-
lowing the development of invasive disease, which
occurs in the context of an established immuno-
privileged state [33]. Tumours with this particular phe-
notype are therefore, in theory, more likely to progress
to muscle-invasive and disseminated disease due to a
dampened host immunological response. Notably,
sTIL levels for all baseline HGT1 cases that prog-
ressed to muscle-invasive disease were high. Compara-
tive analysis of regional immune cell infiltrates and
associated transcriptomic and protein expression will
be required to investigate this finding further. It is also
plausible that regional immune cell infiltrate evaluation
could predict response to targeted agents such as
pembrolizumab with greater efficacy.
We also demonstrated that SCUBE2 was significantly
associated with DSS. This bladder cancer luminal marker
[34], is a secreted tumour suppressor protein that has been
well characterised in breast cancer [35]. SCUBE2 plays a
pivotal role in sonic-hedgehog (Shh) signalling [36],
which is increased in luminal-papillary, low-risk, tumours
[14]. Taken together, this suggests that increased levels
of SCUBE2, and potentially secretion of SCUBE2, could
have a protective effect and therefore favour increased
DSS However, findings from Islam et al (2016) demon-
strated that Shh had the potential to promote tumouri-
genicity via activation of EMT pathways in bladder
cancer. Therefore, the exact role of SCUBE2 in bladder
cancer, as regards Shh signalling, requires further investi-
gation. Additionally, expression levels of RNA are not
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always reflected at the protein level. Therefore, in future
studies, investigation of SCUBE2 protein expression
is required. Given that only four genes were assessed
using RNAScope, our results can only be considered
preliminary.
A major limitation of this study is that the overall
cohort was relatively small. A future multicentre study
is required to provide deeper insight into our findings
and to build on this pilot study. However, despite the
small cohort, FOXA1 was significantly associated with
DSS. When taken together with the previously publi-
shed study, this highlights the potential importance of
FOXA1.
Overall, despite multiple EMT markers being evalu-
ated in our study, no clear association with survival
could be demonstrated. This is in contrast to the
molecular subtype markers and basic spatial
localisation of immune infiltrates within the tissue sec-
tions, where prognostic association, in papillary
regions specifically, was demonstrated. We were ini-
tially surprised that none of the EMT markers assessed
was associated with survival, having hoped to have
elucidated their role in HGT1 disease progression.
Other studies had shown associations between EMT
marker expression in bladder cancer and survival [37–-
39]. Additionally, Otto et al [40] demonstrated that
aberrant E-cadherin expression was predictive of T1
progression. However, EMT is just one mechanism of
tumour progression. Furthermore, Kollberg et al [29]
showed that, at the protein level, the only significant
association with survival with a univariable analysis
was seen for the molecular subtype marker FOXA1
and none of the EMT markers studied. However, it
was not significantly associated with survival in a mul-
tivariable analysis, indicating that FOXA1 warrants
further investigation in future studies.
These initial findings suggest that the identification
of poor prognostic groups using standard clinical labo-
ratory techniques might be best achieved by immune
infiltrate and molecular subtype evaluation as opposed
to EMT markers in HGT1 bladder cancer.
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